Insulin aspart - Biologic Drug Details

Summary for insulin aspart

Tradenames:	2
High Confidence Patents:	18
Applicants:	1
BLAs:	4
Suppliers: see list	4
Recent Clinical Trials:	See clinical trials for insulin aspart
Drug Prices:	Drug price information for insulin aspart

Recent Clinical Trials for insulin aspart

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Yanbing Li	PHASE4
Novo Nordisk A/S	PHASE3
Gan & Lee Pharmaceuticals.	PHASE3

See all insulin aspart clinical trials

Pharmacology for insulin aspart

Established Pharmacologic Class	Insulin Analog
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin aspart Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin aspart Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986	11,311,679	2039-06-25	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986	5,618,913	2006-08-29	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986	5,626,566	2014-03-24	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for insulin aspart Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986	10,004,686	2033-06-12	Patent claims search
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986	10,016,338	2036-12-20	Patent claims search
Novo Nordisk Inc.	NOVOLOG	insulin aspart	Injection	020986	10,118,956	2035-11-30	Patent claims search

International Patents for insulin aspart

Country	Patent Number	Estimated Expiration
Austria	E447992
Australia	2006278928
Brazil	PI0613926

Supplementary Protection Certificates for insulin aspart

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C02107069/02	Switzerland		PRODUCT NAME: INSULIN DEGLUDEC + INSULIN ASPART; REGISTRATION NO/DATE: SWISSMEDIC 62648 12.09.2013
C00214826/01	Switzerland		FORMER REPRESENTATIVE: E. BLUM AND CO. PATENTANWAELTE, CH
132017000073676	Italy		PRODUCT NAME: INSULINA ASPART A RAPIDA AZIONE(FIASP); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1160, 20170111

Executive summary Insulin aspart (marketed mainly as NovoLog and affiliated brands) is a mature, high-volume insulin franchise with declining innovation premium and intensifying competition from (1) insulin aspart co-formulations, (2) next-generation basal insulins, and (3) biosimilar and follow-on products targeting mealtime insulin. The core financial trajectory is driven by geography and payer mix, continued uptake of ultra-rapid and combination regimens, and the rate of erosion from biosimilars and interchangeability policies. Near-term revenue growth, where present, depends less on new mechanism innovation and more on product positioning (formulation, device, and combination therapy) and channel execution rather than patent-led exclusivity expansion.

---

Insulin aspart market dynamics and financial trajectory: what drives revenue growth or erosion

Short answer: Revenue performance for insulin aspart is primarily determined by (i) insulin market volume growth, (ii) switching between prandial insulin brands and competitor mealtime/basal products, (iii) biosimilar entry timing and uptake by plan formularies, and (iv) uptake of insulin aspart delivery formats and co-formulations (including combination products).

What is the product footprint for insulin aspart?

Insulin aspart is a rapid-acting insulin analog used for mealtime glucose control in diabetes, principally:

• Type 1 diabetes (T1D) insulin replacement with prandial dosing
• Type 2 diabetes (T2D) intensification in combination with basal insulin or as part of multi-injection regimens

Which market forces shape utilization?

1. Formulary and rebate dynamics

Last updated: June 25, 2026

• Payers increasingly steer patients toward lower net cost options, including biosimilars/follow-ons.
• Insulin pricing reforms and contracting models tend to increase switching pressure even where clinical differentiation exists.

Competitive substitution

• Rapid-acting competitor insulins (and payer-preferred biosimilars) compete on net price, patient support programs, and device usability.
• Basal insulin competition matters because fixed-ratio and basal intensification strategies can reduce or delay prandial insulin use in T2D.

Patient adherence and device channels

• Pen injectors and co-formulations influence adherence and persistence, which directly affects prescription refills.
• Manufacturer patient programs affect real-world uptake and retention.

Biosimilar landscape pressure

• Where biosimilar or follow-on rapid-acting insulins gain formulary access, unit price realization declines for branded leaders.
• Uptake is typically faster in commercially insured and Medicare Part D through formulary tier placement and contracting.

---

How does insulin aspart financial performance track across regions and payer segments?

Short answer: Insulin aspart revenue is regionally segmented by product access, reimbursement structure, and biosimilar/follow-on penetration. High-income markets with active biosimilar procurement typically show earlier branded erosion than markets with slower substitution.

Commercial versus government payers

• Commercial insurance: Higher likelihood of payer-driven switching via formulary contracting and step-edit policies.
• Medicare/Part D and government tenders: Commonly accelerate price competition when biosimilars are treated as preferred options.
• Emerging markets: Often show different channel dynamics driven by procurement cycles and product availability, delaying biosimilar substitution in some jurisdictions.

Geography-specific drivers

• United States: Payer formulary pressure and biosimilar entry timing are the primary drivers of brand revenue changes.
• Europe: Tendering and reimbursement systems drive net price reductions and accelerated substitution when biosimilars become preferred.
• Japan and other advanced markets: Typically see less abrupt switching than the U.S., but biosimilar availability and local contracting still compress branded economics.

---

What is the Orange Book status of insulin aspart, and how does that affect biosimilar and generic competition?

Short answer: Insulin aspart is a biologic, so Orange Book (which covers small molecules) is not the relevant exclusivity/patent status framework. The controlling public record is generally the biologics pathway and patent listing mechanisms in the U.S. that govern biosimilar litigation and exclusivity.

U.S. regulatory status affects substitution risk

• Biosimilars follow the Biologics Price Competition and Innovation Act (BPCIA) framework.
• Substitution depends on interchangeability designations, formularies, and real-world clinician and patient acceptance, not Orange Book listings.

Why this matters for financial trajectory

• Branded revenue is pressured when biosimilar products gain:
  • favorable formulary tiers,
  • broader reimbursement access,
  • and, in some cases, interchangeability status that enables pharmacy-level substitution.

---

When does insulin aspart lose exclusivity, and what does that mean for revenue erosion timing?

Short answer: For mature biologics like insulin aspart, exclusivity and patent protection typically provide staggered protection for:

• the active ingredient,
• specific formulations or devices,
• manufacturing processes,
• and method-of-use claims.

Once the last relevant protection is overcome or expires, biosimilar entry becomes a structural risk to branded pricing and share.

Typical exclusivity-to-revenue translation

• Before patent/patent-litigation resolution: biosimilar adoption is limited; branded revenue remains protected by delayed entry.
• After entry launch: net price declines occur quickly as payers adjust formularies.
• After uptake maturity (12-36 months): volume share erosion stabilizes, and brand revenue becomes more dependent on patient retention, device preference, and combination-product pull-through.

---

Which companies are challenging insulin aspart, and what does their market entry strategy imply?

Short answer: In biologics, challengers are biosimilar sponsors using the BPCIA pathway. Their strategies usually focus on:

• rapid scale-up post-approval,
• contracting for payer formularies,
• and product differentiation through patient support and distribution.

What “challenge” usually means in practice

• Filing for biosimilar approval under the appropriate regulatory pathway.
• Patent litigation and settlement agreements that set launch timing and market positioning.
• Post-approval market access efforts to convert approval into payer-driven volume.

---

What formulations and co-formulations of insulin aspart change competitive outcomes?

Short answer: The competitive landscape for insulin aspart includes formulation-level differentiation and combination products that affect ease of use and payer contracting.

Key formulation categories that move the revenue needle

1. Ultra-rapid mealtime presentations
   • Impact adherence and postprandial glucose control perceptions.
2. Premixed insulin aspart regimens
   • Often used for simplified dosing schedules in T2D.
3. Combination products
   • Fixed-ratio strategies can reduce total injection burden and shift treatment pathways.

Financial implication

Formulation and co-formulation product sets can sustain branded revenue longer than the “naked” active ingredient because payers contract by regimen convenience and total cost-of-therapy.

---

How do insulin aspart method-of-use patents and combination therapy claims affect biosimilar entry?

Short answer: Method-of-use and combination therapy patents can delay market entry for biosimilars even after active-ingredient patent coverage ends, depending on claim scope, notice provisions, and litigation results.

What claim types matter most

• T1D/T2D dosing or titration regimens
• Combination use with specific basal insulins or adjunct therapies
• Device-linked instructions (where applicable)
• Clinical endpoints tied to defined regimens

Financial implication for the branded portfolio

If branded firms preserve pathway access through method-of-use or combination-specific coverage, they can reduce the effective penetration window for biosimilars, slowing immediate net price compression.

---

What patent litigation affects insulin aspart, and how do settlements shift launch timing?

Short answer: Biosimilar litigation in insulin analogs typically resolves via:

• dismissal/settlement,
• delayed entry under court-approved timelines,
• or design-around strategies that affect commercial launch timing.

Why settlements matter for revenue

• Settlement terms usually define earliest permitted launch dates and sometimes geographic scope.
• Commercially, branded revenue tends to remain higher until the settlement end date, then drop at biosimilar launch and contract renegotiation.

---

What is the FDA regulatory status of insulin aspart, and how does that interact with payer adoption?

Short answer: Insulin aspart is approved for mealtime use in diabetes; its regulatory status supports broad clinical use. The limiting factor for biosimilar-driven changes is not approval readiness, but payer contracting and interchangeability decisions.

Device and administration pathways

• Pen delivery drives adherence and can lock in prescribing habits through patient support programs.
• Biosimilar uptake depends on ensuring comparable delivery usability and distribution coverage.

Financial implication

Even when biosimilars launch, payer adoption depends on:

• net price,
• formulary placement,
• and prescriber comfort with interchangeability.

---

How does insulin aspart compare with competing rapid-acting and basal insulins in market and revenue impact?

Short answer: Insulin aspart competes directly with other rapid-acting analogs and indirectly with basal insulin intensification approaches that reduce or delay prandial dosing in T2D.

Competitive substitution map (high-level)

• Direct mealtime competitors: Other rapid-acting insulin analogs and their biosimilar/follow-on versions.
• Indirect competition: Basal insulin intensification, fixed-ratio combinations, and alternative regimens that restructure prandial insulin demand.

Practical business effect

• Branded mealtime insulins face more direct price compression once biosimilars enter.
• Revenue stability is improved when insulin aspart maintains a strong position in T1D and remains embedded in combination regimens for T2D.

---

Generic or biosimilar entry risks for insulin aspart: what drives fast or slow erosion?

Short answer: Erosion speed depends on interchangeability, formulary depth, payer contracting aggressiveness, and patient retention programs.

Erosion risk accelerators

• Multiple biosimilar entrants, increasing competitive bidding pressure
• Preferred formulary tier placement
• Pharmacy-level substitution where interchangeability applies
• Aggressive patient switching campaigns with low co-pays

Erosion risk slowdowns

• Branded pen ecosystem and patient support entrenchment
• Complex clinical considerations and prescriber preference
• Formulary restrictions requiring prior authorization or step edits

---

What are the key revenue drivers for insulin aspart in the next 24-48 months?

Short answer: The next phase of financial trajectory is shaped by:

• biosimilar/follow-on adoption rates,
• payer strategy on total insulin cost,
• and continued use of co-formulations and delivery platforms that preserve adherence and persistence.

Revenue driver checklist (what matters commercially)

• Net price realization: branded discounting vs biosimilar price competition
• Volume retention: persistence in T1D and regimen stickiness in T2D
• Contracting outcomes: formulary tiering and rebate structures
• Channel access: managed care coverage and pharmacy distribution coverage
• Portfolio mix: shift between aspart-only vs premix vs combination regimens

---

Key takeaways

• Insulin aspart is a mature biologic with revenue trajectory increasingly governed by payer contracting and biosimilar uptake rather than new innovation.
• The fastest branded erosion occurs when biosimilars gain preferred formulary access and broader substitution pathways.
• Formulation and regimen positioning, especially co-formulations and combination strategies, can extend revenue by improving regimen stickiness and adherence.
• Financial outlook is driven by net price realization, volume retention, and contract renewals, with competitive pressure accelerating as biosimilar penetration increases.

---

FAQs

1. How do biosimilar interchangeability decisions change insulin aspart pharmacy substitution and revenue impact?
2. Which payer contract levers most strongly influence insulin aspart formulary tiering for mealtime insulin?
3. How does switching between premixed insulin aspart and basal-plus-prandial regimens affect market share?
4. What manufacturing and supply chain constraints typically influence biosimilar insulin aspart launch scale and uptake?
5. How do device ecosystem differences (pens, delivery systems) affect real-world insulin aspart persistence after biosimilar entry?

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Biologics Price Competition and Innovation Act (BPCIA) and biosimilar regulatory framework. FDA.
2. U.S. Food and Drug Administration. (n.d.). Biosimilar and interchangeable products: regulatory guidance and pathways. FDA.
3. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). (n.d.). Biosimilar adoption and payer decision-making literature. ISPOR.